Newswise — [FORT WASHINGTON, PA – March 24, 2017] The NCCN Foundation® has awarded grants to four young investigators from National Comprehensive Cancer Network® (NCCN®) Member Institutions. These awardees, who are dedicated to advancing and discovering new treatments for cancer, enhancing quality, and improving patient education, represent the seventh series of NCCN Foundation Young Investigator Awards—a program initiated in 2011. The grants will provide $150,000 in funding over a two-year period to each awardee, beginning in July 2017.

“The NCCN Foundation is excited to award these funds to support career development of the next generation of innovators at the forefront of their field. These researchers are guiding the course of treatment innovation and advancement for all people with cancer,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation.

Following are the 2017 NCCN Foundation Young Investigator Award recipients: • Kemi Doll, MD, MSCR, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, “Racial Disparities in Endometrial Cancer”• Saad Kenderian, MB, CHB, Mayo Clinic Cancer Center, “Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia: Mechanisms of Resistance and Strategies to Enhance Efficacy”• Florian Muller, PhD, The University of Texas MD Anderson Cancer Center, “ENO1-Deletion as a Target for Personalized Oncology: Collateral Lethality to the Clinic”• Elizabeth Stewart, MD, St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, “Preclinical Match”

The awardees responded to a Request for Proposals issued by the NCCN Foundation to the NCCN Member Institutions and were nominated by their institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts; the awardees were selected based on several key components, including scientific merit and study design. The studies will be managed and overseen by the NCCN Oncology Research Program (ORP).

Since its inception in 2011, NCCN Foundation has provided funding to 35 U.S. researchers through the Young Investigator Awards. On March 23 and 24, 2017, NCCN featured abstracts from the fifth series of Young Investigator Awards recipients during the NCCN 22nd Annual Conference General Poster Session in Orlando, Florida.

The 2017 NCCN Foundation Young Investigator Awards were made possible through support from AbbVie Inc., Amgen Inc., Merck & Co. Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and Pfizer Inc.

For more information about the NCCN Young Investigator Awards, visit

###About NCCN FoundationNCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. NCCN Foundation supports people with cancer and their caregivers at every step of their treatment journey by delivering unbiased expert guidance from the world’s leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising young investigators at the forefront of cancer research, initiating momentum in their careers and furthering the betterment of patients through their groundbreaking innovations. For more information about NCCN Foundation, visit

About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit Patients and caregivers, visit Media, visit